A principal investigator with Egypt’s Benha University and team recently concluded a clinical trial titled ‘Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic.’ The results, now available on the preprint server, are promising. Dr. Ahmed Elgazzar and a team, including other investigators from Benha University, have yet again verified in a well-designed clinical trial that the addition of anti-parasite drug Ivermectin to standard of care is in fact, an effective drug for the treatment of COVID-19 patients. The Egyptian-based research group declared that the study drug led to a reduction in mortality compared to only Hydroxychloroquine plus standard treatment. Moreover, the team now declares that early use of Ivermectin is not only effective for controlling COVID-19 infections but also as prophylaxis as well as contributing to the improvement of the potentially deadly cytokine storm. Health regulatory authorities and research agencies should acknowledge the mounting evidence for this effective and economical drug and immediately invest in research in more advanced economies such as the United States.
The Study Lead
This study is one o...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).